Co-Founder of Faeth Therapeutics; Chief Operating Officer and Director, Sensei Biotherapeutics
Appears in 1 story
Leading combined company's PIKTOR program as COO
Lewis Cantley discovered the PI3K enzyme in 1985. Four decades later, a combination therapy targeting multiple nodes of the pathway he uncovered just demonstrated an 80% response rate in endometrial cancer patients—triple the historical rate with chemotherapy alone. Sensei Biotherapeutics acquired Faeth Therapeutics and raised $200 million to push this approach through pivotal trials.
Updated Feb 18
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
